Lynce, Filipa http://orcid.org/0000-0001-6615-7076
Mainor, Candace http://orcid.org/0000-0002-4431-7101
Donahue, Renee N. http://orcid.org/0000-0002-6828-3073
Geng, Xue http://orcid.org/0000-0003-4100-9899
Jones, Greg http://orcid.org/0000-0001-9652-0294
Schlam, Ilana http://orcid.org/0000-0003-4996-0400
Wang, Hongkun
Toney, Nicole J.
Jochems, Caroline http://orcid.org/0000-0002-9000-9855
Schlom, Jeffrey http://orcid.org/0000-0001-7932-4072
Zeck, Jay http://orcid.org/0009-0007-8847-7223
Gallagher, Christopher http://orcid.org/0000-0002-3846-5052
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Graham, Deena http://orcid.org/0000-0003-1111-6984
Stringer-Reasor, Erica M.
Denduluri, Neelima http://orcid.org/0000-0002-6075-6809
Collins, Julie http://orcid.org/0000-0001-5702-4693
Chitalia, Ami http://orcid.org/0009-0001-0274-2150
Tiwari, Shruti
Nunes, Raquel http://orcid.org/0000-0002-0552-1644
Kaltman, Rebecca
Khoury, Katia http://orcid.org/0000-0003-3899-8649
Gatti-Mays, Margaret
Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Swain, Sandra M. http://orcid.org/0000-0002-1320-3830
Pohlmann, Paula
Parsons, Heather A. http://orcid.org/0000-0001-8178-6612
Isaacs, Claudine http://orcid.org/0000-0002-9646-1260
Funding for this research was provided by:
Georgetown University
Article History
Received: 5 January 2023
Accepted: 15 March 2024
First Online: 27 March 2024
Competing interests
: F.L. reports consulting/advisory role for AstraZeneca, Pfizer, Merck and Daiichi Sankyo; and institutional research funding from Eisai, AstraZeneca, CytomX and Gilead Sciences. M.G.M. reports consulting/advisory roles for GE and Seagen. G.J. reports being a shareholder and employee of NeoGenomics. C.G. reports serving on advisory boards for AstraZeneca, Daiichi Sankyo and Lilly Oncology. R.Na reports serving on advisory boards for AstraZeneca, BeyondSpring, Fujifilm, GE, Gilead, Infinity, iTeos, Merck, OBI, Oncosec, Sanofi and Seagen; and reports research funding from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Gilead/Immunomedics, Merck, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma and Taiho. E.S.-R. reports serving as a consultant for Lilly, Mylan, Novartis, Immunomedics, AstraZeneca, Seagen, and Merck; and institutional research funding from Susan G. Komen, V Foundation, Breast Cancer Research Foundation of Alabama and the National Institutes of Health. N.D., J.C., and R.Nu report current employment with AstraZeneca. P.T. reports advisory/consultancy roles for AstraZeneca, Daiichi Sankyo and Lilly. S.M.T. reports consulting or advisory roles for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Sumitovant Biopharma, Zetagen, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, and Hengrui USA; research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep; and travel support from Eli Lilly, Sanofi, Gilead, and Pfizer. S.M.S. reports serving on advisory boards with honorarium at AstraZeneca, Daiichi-Sankyo, Aventis, Silverback Therapeutics, Genentech/Roche, Merck, Biotheranostics, Natera, Lilly, Molecular Templates and Exact Sciences; institutional research funding from Kailos Genetics and Genentech/Roche; third party in-kind writing from Genentech/Roche and AstraZeneca; and stock and stock options from Seagen. P.P. reports consulting for BOLT Therapeutics, AbbVie and Perthera; and serving as an unpaid steering committee member of a clinical trial for Seagen. H.A.P. reports institutional research funding from Puma Biotechnology and serving on the advisory board of Illumina. C.I. reports consulting for Genentech, PUMA, Seattle Genetics, AstraZeneca, Novartis, Pfizer, ESAI, Sanofi, ION and Gilead; royalties from Wolters Kluwer (UptoDate) and McGraw Hill (Goodman and Gillman); institutional research support from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech and Novartis; and serving as a medical director for the Side-Out Foundation. The remaining authors declare no competing interests.